|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 39/395 | (2006.01) |
| C07K 16/28 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 2268310 |
| (13) | Kind of document | T |
| (96) | European patent application number | 09723808.3 |
| Date of filing the European patent application | 2009-03-23 | |
| (97) | Date of publication of the European application | 2011-01-05 |
| (45) | Date of publication and mention of the grant of the patent | 2016-07-20 |
| (46) | Date of publication of the claims translation | 2016-09-26 |
| (86) | Number | PCT/EP2009/002111 |
| Date | 2009-03-23 |
| (87) | Number | WO 2009/118142 |
| Date | 2009-10-01 |
| (30) | Number | Date | Country code |
| 08005554 | 2008-03-25 | EP | |
| 08007172 | 2008-04-11 | EP |
| (72) |
DUMONTET, Charles, FR
FRIESS, Thomas, DE
HERTING, Frank, DE
KLEIN, Christian, CH
UMANA, Pablo, CH
|
| (73) |
Roche Glycart AG,
Wagistrasse 18, 8952 Schlieren-Zuerich,
CH
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Panaudojimas II tipo anti-CD20 antikūnų su padidėjusiu nuo antikūnų priklausomu ląsteliniu citotoksiškumu (ADCC) derinyje su ciklofosfamidu, vinkristinu ir doksorubicinu ne-Hodžkino limfomos gydymui |
| USE OF A TYPE II ANTI-CD20 ANTIBODY WITH INCREASED ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) IN COMBINATION WITH CYCLOPHOSPHAMIDE, VINCRISTINE AND DOXORUBICINE FOR TREATING NON-HODGKIN` S LYMPHOMAS |
| Payment date | Validity (years) | Amount | |
| 2025-02-18 | 17 | 347.00 EUR |
| 2026-03-23 |